LAUSANNE, Switzerland, September 8, 2011 /PRNewswire/ --
Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, will present tomorrow the 'Debiopharm Group Life Sciences Award 2011' to Professor Stefano Piccolo as well as two inaugural 'Junior Debiopharm Group Life Sciences Awards 2011' to Professor Etienne Meylan and Doctor Volker Busskamp. The award ceremony will take place at the EPFL (Ecole polytechnique fédérale de Lausanne) during the ISREC (Swiss Institute for Experimental Cancer Research) 2011 Life Sciences Symposium entitled 'Hallmarks and horizons of cancer'.
The 'Debiopharm Group Life Sciences Award 2011' is granted to Professor Stefano Piccolo from the University of Padua, Italy. He has made extensive contributions to the field of cancer, in particular in dissecting the role of a protein secreted by cells called "transforming growth factor beta (TGFb)", and the relation of TGFb to intracellular signalling pathways involved in cancer initiation and progression. Professor Piccolo is now working on the role of small RNAs called microRNAs or miRNAs in controlling overall cell signalling. The award amounts to CHF 50'000.- of which CHF 40'000.- are made available to the awardee's institute, whilst CHF 10'000.- are for personal use.
This year, Debiopharm decided to launch the inaugural 'Junior Debiopharm Group Life Sciences Awards'. Professor Etienne Meylan from the EPFL and Doctor Volker Busskamp from the Basel-based Friedrich Miescher Institute for Biomedical Research (FMI), are the recipients of the 'Junior Debiopharm Group Life Sciences Awards'. Each award amounts to CHF 25'000.- of which CHF 20'000.- are made available to the awardees' respective institutes, whilst CHF 5'000.- are for personal use. The junior awards are destined to young researchers in Switzerland, in the field of cellular and molecular biology. They are ideal
|SOURCE The Debiopharm Group|
Copyright©2010 PR Newswire.
All rights reserved